Studienliteratur zum Neuroblastom

Zuletzt geändert: 13.05.2026 https://kinderkrebsinfo.de/doi/e123832

Studienliteratur Neuroblastome

Pubmed

  1. Schroeer AM, Winkler A, Fillies M, Kranig C, Karaman E, von Stetten F, Zengerle R, Lehnert M, Blume A, Hollander JF, Lodrini M, Eggert A, Akalin A, Astrahantseff K, Eckert C, Deubzer HE, Szymansky A: Multiplexed biomarkers dynamically detect heterogeneous residual neuroblastoma cell clone activity in the bone marrow niche. Cancer letters 2026, 645: 218352 [PMID: 41740832] SCH2026a
  2. Cohn SL, London WB, Schleiermacher G, Moreno L, Ambros IM, Ambros PF, Bagatell R, Popovic MB, Beiske KH, Berthold F, Birz S, Brisse HJ, Brodeur GM, Brock PR, Burchill S, Eggert A, Federico SM, Fischer M, Furner BT, Hero B, Machin D, Kamijo T, Matthay KK, Nakagawara A, Naranjo A, Pötschger U, Valteau-Couanet D, Watkins MT, Irwin MS, Volchenboum SL, Park JR, Pearson ADJ: International neuroblastoma risk group consortium: a model of networking for rare cancers. Journal of the National Cancer Institute 2026, 118: 579 [PMID: 40854111] COH2026
  3. Saint-Charles A, Masliah-Planchon J, Saberi-Ansari E, Bellini A, Bernkopf M, Font de Mora J, Noguera R, Van Roy N, Goodman A, Vicha A, Attignon V, Combaret V, Beiske K, Martinsson T, Schoumans J, Rossing M, Tops B, Westermann F, Cotteret S, Fischer M, Birger Y, Mazzocco K, Chesler L, Betts D, Cowley M, Capasso M, Bobin C, Iddir Y, Zaidi S, Carcaboso AM, Vandermeulen J, Loontiens S, Gaarder J, Ibrahim RR, Rosswog C, Hameiri-Grossman M, Shichrur K, Trahair T, Barahona P, Eggert A, Deubzer HE, Delattre O, Pasqualini C, George S, Tytgat G, Tweddle DA, Taschner-Mandl S, Schleiermacher G: Harmonization of Reporting of ALK Genetic Alterations in Neuroblastoma: A SIOPEN Biology Study. The Journal of molecular diagnostics : JMD 2026, 28: 27 [PMID: 41110766] SAI2026
  4. Castelli S, Schulze F, Thole-Kliesch TM, Astrahantseff K, Barone G, Beck-Popovic M, Berlanga P, Corbacioglu S, Fischer M, Gambart M, George SL, Chesler L, Gray JC, Hero B, Künkele A, Flaadt T, Lang P, Lode HN, Molenaar JJ, Schleiermacher G, Rosswog C, Moreno L, Owens C, Rubio-San-Simón A, Schulte JH, Simon T, Tweddle DA, Deubzer HE, Eggert A, SIOPEN New Drug Development, Immunotherapy and Relapse Groups: Current treatment strategies for first relapse of high-risk neuroblastoma. European journal of cancer (Oxford, England : 1990) 2026, 236: 116254 [PMID: 41643518] WER2026
  5. Werr L, Boland J, Petersen J, Iglesias F, Höppner S, Bartenhagen C, Rosswog C, Hellmann AM, Kahlert Y, Hemstedt N, Ibruli N, Dammert MA, Decarolis B, Werner JM, Malchers F, Schramm K, Witt O, Beiske KH, Rognlien AGW, Gunnes MW, Langenberg KP, Molenaar J, Bernkopf M, Taschner-Mandl S, Hughes D, George SL, Chesler L, Schulte JH, Barone G, Capasso M, Surrey LF, Bagatell R, Masliah-Planchon J, Schleiermacher G, Grüll H, Westermann F, Schultheis AM, Büttner R, Henssen AG, Eggert A, Peifer M, Shukla NN, Simon T, Hero B, Reinhardt HC, Thomas RK, Fischer M: Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma. The Journal of clinical investigation 2026, 136 [PMID: 41678281] WER2026
  6. Ludwig M, Ahrens K, Winkler A, Wünschel J, Ruka P, Lodrini M, Hertwig F, Castelli S, Thole-Kliesch TM, Hollander JF, Fuchs S, Künkele A, Jens M, Mamlouk S, Warmann SW, Astrahantseff K, Eggert A, Schulte JH, Szymansky A, Deubzer HE: YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells. Cancers 2026, 18 [PMID: 41681855] LUD2026
  7. Rieke DT, Schwartz S, Ochsenreither S, Chapuy B, Amthauer H, Deubzer HE, Lehmann A, Keilholz U, Wardelmann E, Vokuhl C, Eggert A, Fröhling S, Horst D, Capper D, Keller U, Dragomir MP, Schallenberg S: Comprehensive molecular analyses for diagnosis and treatment guidance in an adult neuroblastoma patient. The oncologist 2026 Apr 7; [PMID: 41950381] RIE2026
  8. Castelli S, Schulze F, Thole-Kliesch TM, Astrahantseff K, Barone G, Beck-Popovic M, Berlanga P, Corbacioglu S, Fischer M, Gambart M, George SL, Chesler L, Gray JC, Hero B, Künkele A, Flaadt T, Lang P, Lode HN, Molenaar JJ, Schleiermacher G, Rosswog C, Moreno L, Owens C, Rubio-San-Simón A, Schulte JH, Simon T, Tweddle DA, Deubzer HE, Eggert A, SIOPEN New Drug Development, Immunotherapy and Relapse Groups: Current treatment strategies for first relapse of high-risk neuroblastoma. European journal of cancer 2026, 236: 116254 [PMID: 41643518] CAS2026
  9. Andersch L, Grunewald L, Stecklum M, Klironomos F, Haase K, Hollek V, Lam T, Jung BA, Winkler A, Schwiebert S, Astrahantseff K, Launspach M, Jens M, Henssen A, Kloke L, Blüthgen N, Eggert A, Schulte JH, Anders K, Künkele A: Investigating genetic modifications to enhance L1CAM-CAR T cell migration in solid tumors in a 3D bioprinted neuroblastoma model. Frontiers in immunology 2025, 16: 1677361 [PMID: 41394860] AND2025a
  10. Gelineau NU, van Zogchel LMJ, De Carolis B, van Wezel EM, Zappeij-Kannegieter L, Javadi A, Schumacher-Kuckelkorn R, Simon T, Berthold F, van Noesel MM, Fiocco M, Stutterheim J, Ellen van der Schoot C, Hero B, Tytgat GAM: Minimal Residual Disease Detection in Peripheral Blood of Patients With High-Risk Neuroblastoma Correlates With Outcome in the International GPOH-DCOG Prospective Validation Study. JCO precision oncology 2025, 9:e2500235 [PMID: 41411610] GEL2025
  11. Hollander JF, Szymansky A, Wünschel J, Astrahantseff K, Rosswog C, Thorwarth A, Thole-Kliesch TM, Chamorro González R, Hundsdörfer P, Hauptmann K, Schmelz K, Gürgen D, Rogasch JMM, Henssen AG, Fischer M, Schulte JH, Eckert C, Eggert A, Lodrini M, Deubzer HE: Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. Cancer research communications 2025, 5: 167 [PMID: 39760332] HOL2025
  12. Flaadt T, Rehm J, Simon T, Hero B, Ladenstein RL, Lode HN, Grabow D, Nolte S, Crazzolara R, Greil J, Ebinger M, Abele M, Holzer U, Döring M, Schulte JH, Bader P, Schlegel PG, Eyrich M, Lang P, Klingebiel T, Handgretinger R: Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study. Cancers 2025, 17 [PMID: 39796776] FLA2025
  13. Grunewald L, Andersch L, Helmsauer K, Schwiebert S, Klaus A, Henssen AG, Straka T, Lodrini M, Wicha SG, Fuchs S, Hertwig F, Westermann F, Vitali A, Caramel C, Büchel G, Eilers M, Astrahantseff K, Eggert A, Höpken UE, Schulte JH, Blankenstein T, Anders K, Künkele A: Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy. Pharmacological research 2025, 212: 107608 [PMID: 39828101] GRU2025
  14. Kleen K, Gebauer J, Spix C, Kronziel LL, König I, Baust K, Calaminus G, Simon T, Hero B, Zolk O, Graf N, Abdul-Khaliq H, Langer T: Anthracycline-Induced Cardiomyopathy After Nephro-/Neuroblastoma in Childhood: The Importance of Cardiological Reference Assessment. Cancer medicine 2025, 14:e71158 [PMID: 40832779] KLE2025
  15. Simon T, Thole T, Castelli S, Timmermann B, Jazmati D, Schwarz R, Fuchs J, Warmann S, Hubertus J, Schmidt M, Rogasch J, Körber F, Vokuhl C, Schäfer J, Schulte JH, Deubzer H, Rosswog C, Fischer M, Lang P, Langer T, Astrahantseff K, Lode H, Hero B, Eggert A: GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025. Klinische Padiatrie 2025, 237: 117 [PMID: 40345224] SIM2025
  16. Sprokkerieft J, van der Beek JN, Spreafico F, Selle B, Chowdhury T, Graf N, Verschuur AC, Dandis R, Bex A, Geller JI, Tytgat GAM, van den Heuvel-Eibrink MM: Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review. Critical reviews in oncology/hematology 2024, 204: 104523 [PMID: 39326645] SPR2024
  17. Sprüssel A, Suzuki T, Miyata N, Astrahantseff K, Szymansky A, Toedling J, Thole-Kliesch TM, Ballagee A, Lodrini M, Künkele A, Truss M, Heukamp LC, Mathia S, Hertwig F, Rosenberger C, Eggert A, Deubzer HE, Schulte JH: Targeting KDM1A in Neuroblastoma with NCL-1 Induces a Less Aggressive Phenotype and Suppresses Angiogenesis. Journal of clinical medicine 2024, 13 [PMID: 39458030] SPR2024
  18. Flaadt T, Ebinger M, Schreiber M, Ladenstein RL, Simon T, Lode HN, Hero B, Schuhmann MU, Schäfer J, Paulsen F, Timmermann B, Eggert A, Lang P: Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse. Journal of clinical medicine 2023, 12 [PMID: 37834840] FLA2023
  19. Jazmati D, Brualla L, Littooij AS, Webber B, Dieckmann K, Janssens GO, Simon T, Gaze MN, Merta J, Serrano A, Dietzsch S, Kramer PH, Wulff J, Boterberg T, Timmermann B: Overcoming inter-observer planning variability in target volume contouring and dose planning for high-risk neuroblastoma - a European multicenter effort of the SIOPEN radiotherapy committee. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2023, 181: 109464 [PMID: 36640946] JAZ2023
  20. Rosswog C, Fassunke J, Ernst A, Schömig-Markiefka B, Merkelbach-Bruse S, Bartenhagen C, Cartolano M, Ackermann S, Theissen J, Blattner-Johnson M, Jones B, Schramm K, Altmüller J, Nürnberg P, Ortmann M, Berthold F, Peifer M, Büttner R, Westermann F, Schulte JH, Simon T, Hero B, Fischer M: Genomic ALK alterations in primary and relapsed neuroblastoma. British journal of cancer 2023, 128: 1559 [PMID: 36807339] ROS2023
  21. Körber V, Stainczyk SA, Kurilov R, Henrich KO, Hero B, Brors B, Westermann F, Höfer T: Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome. Nature genetics 2023, 55: 619 [PMID: 36973454] KOE2023
  22. Lode HN, Ladenstein R, Troschke-Meurer S, Struppe L, Siebert N, Zumpe M, Ehlert K, Huber S, Glogova E, Hundsdoerfer P, Eggert A, Zaniewska-Tekieli A, Balwierz W, Wieczorek A: Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy. Cancers 2023, 15 [PMID: 37444475] LOD2023
  23. Butzer SK, Krug B, Reisberg M, Fuchs J, Warmann SW, Hubertus J, Körber F, Berthold F, Simon T, Hero B: Image-defined risk factors in localized thoracic neuroblastoma and ganglioneuroma. Pediatric blood & cancer 2023, 70:e30605 [PMID: 37534915] BUT2023
  24. Schmidt M, Decarolis B, Franzius C, Hero B, Pfluger T, Rogasch JMM, Simon T: Durchführung und Befundung der 123I-mIBG-Szintigraphie bei Kindern und Jugendlichen mit Neuroblastom (Version 3) – DGN-Handlungsempfehlung (S1-Leitlinie), Stand: 2/2020 – AWMF-Registernummer: 031-040. Nuklearmedizin. Nuclear medicine 2022, 61: 96 [PMID: 35421899] SCH2022d
  25. Zolk O, von dem Knesebeck A, Graf N, Simon T, Hero B, Abdul-Khaliq H, Abd El Rahman M, Spix C, Mayer B, Elsner S, Gebauer J, Langer T: Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study. JMIR research protocols 2022, 11:e27898 [PMID: 35175211] ZOL2022
  26. Lodrini M, Wünschel J, Thole-Kliesch TM, Grimaldi M, Sprüssel A, Linke RB, Hollander JF, Tiburtius D, Künkele A, Schulte JH, Lankes E, Elgeti T, Hundsdörfer P, Astrahantseff K, Simon T, Eggert A, Deubzer HE: Circulating Cell-Free DNA Assessment in Biofluids from Children with Neuroblastoma Demonstrates Feasibility and Potential for Minimally Invasive Molecular Diagnostics. Cancers 2022, 14 [PMID: 35565208] LOD2022
  27. Berlak M, Tucker E, Dorel M, Winkler A, McGearey A, Rodriguez-Fos E, da Costa BM, Barker K, Fyle E, Calton E, Eising S, Ober K, Hughes D, Koutroumanidou E, Carter P, Stankunaite R, Proszek P, Jain N, Rosswog C, Dorado-Garcia H, Molenaar JJ, Hubank M, Barone G, Anderson J, Lang P, Deubzer HE, Künkele A, Fischer M, Eggert A, Kloft C, Henssen AG, Boettcher M, Hertwig F, Blüthgen N, Chesler L, Schulte JH: Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. Molecular cancer 2022, 21: 126 [PMID: 35689207] BER2022
  28. Meeser A, Bartenhagen C, Werr L, Hellmann AM, Kahlert Y, Hemstedt N, Nürnberg P, Altmüller J, Ackermann S, Hero B, Simon T, Peifer M, Fischer M, Rosswog C: Reliable assessment of telomere maintenance mechanisms in neuroblastoma. Cell & bioscience 2022, 12: 160 [PMID: 36153564] MEE2022
  29. Sorrentino S, Ash S, Haupt R, Plantaz D, Schiff I, Hero B, Simon T, Kachanov D, Shamanskaya T, Kraal K, Littooij A, Wieczoreck A, Balwierz W, Laureys G, Trager C, Sertorio F, Erminio G, Fragola M, Beck Popovic M, De Bernardi B, Trahair T: Presenting features of neuroblastoma with spinal canal invasion. A prospective study of the International Society of Pediatric Oncology Europe - Neuroblastoma (SIOPEN). Frontiers in pediatrics 2022, 10: 1023498 [PMID: 36299690] SOR2022
  30. Jazmati D, Hero B, Thole-Kliesch TM, Merta J, Deubzer HE, Bäumer C, Heinzelmann F, Schleithoff SS, Koerber F, Eggert A, Schwarz R, Simon T, Timmermann B: Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry. Current oncology 2022, 29: 8222 [PMID: 36354709] JAZ2022
  31. Schmelz K, Toedling J, Huska M, Cwikla MC, Kruetzfeldt LM, Proba J, Ambros PF, Ambros IM, Boral S, Lodrini M, Chen CY, Burkert M, Guergen D, Szymansky A, Astrahantseff K, Kuenkele A, Haase K, Fischer M, Deubzer HE, Hertwig F, Hundsdoerfer P, Henssen AG, Schwarz RF, Schulte JH, Eggert A: Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions. Nature communications 2021, 12: 6804 [PMID: 34815394] SCH2021g
  32. Schumacher-Kuckelkorn R, Atra A, Belli ML, den Engelsman G, Fréneaux P, Gauthier A, Heijlaerts-Klever A, Scuderi F, Senent Peris L, Tewari S, Zapletal O, Ernst A, Berthold F: The reliability of bone marrow cytology as response criterion in metastatic neuroblastoma. Pediatric blood & cancer 2021, 68:e28819 [PMID: 33245195] SCH2021d
  33. Jazmati D, Butzer S, Hero B, Doyen J, Ahmad Khalil D, Steinmeier T, Schulze Schleithoff S, Eggert A, Simon T, Timmermann B: Long-term follow-up of children with neuroblastoma receiving radiotherapy to metastatic lesions within the German Neuroblastoma Trials NB97 and NB 2004. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2021, 197: 683 [PMID: 33300099] JAZ2021a
  34. Berthold F, Rosswog C, Christiansen H, Frühwald M, Hemstedt N, Klingebiel T, Fröhlich B, Schilling FH, Schmid I, Simon T, Hero B, Fischer M, Ernst A: Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification. Pediatric blood & cancer 2021, 68:e29038 [PMID: 33826231] BER2021a
  35. Schulte JH, Eggert A: ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside. Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Jul 1; 27: 3507 [PMID: 33947691] SCH2021a
  36. Arlt B, Zasada C, Baum K, Wuenschel J, Mastrobuoni G, Lodrini M, Astrahantseff K, Winkler A, Schulte JH, Finkler S, Forbes M, Hundsdoerfer P, Guergen D, Hoffmann J, Wolf J, Eggert A, Kempa S, Deubzer HE: Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma. International journal of cancer 2021, 148: 1219 [PMID: 33284994] ARL2021
  37. Launspach M, Seif M, Thole TM, Jesse P, Schulz J, Schulte JH, Bischoff S, Eggert A, Deubzer HE: Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma. Children (Basel, Switzerland) 2021, 8 [PMID: 33572828] LAU2021
  38. Berthold F, Spix C, Erttmann R, Hero B, Michaelis J, Treuner J, Ernst A, Schilling FH: Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial. JNCI cancer spectrum 2021, 5:pkab041 [PMID: 34240006] BER2021
  39. Zirngibl F, Ivasko SM, Grunewald L, Klaus A, Schwiebert S, Ruf P, Lindhofer H, Astrahantseff K, Andersch L, Schulte JH, Lode HN, Eggert A, Anders K, Hundsdoerfer P, Künkele A: GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma. Journal for immunotherapy of cancer 2021, 9 [PMID: 34285106] ZIR2021
  40. Moroz V, Machin D, Hero B, Ladenstein R, Berthold F, Kao P, Obeng Y, Pearson ADJ, Cohn SL, London WB: The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric blood & cancer 2020, 67:e28359 [PMID: 32472746] MOR2020a
  41. Matthyssens LE, Nuchtern JG, Van De Ven CP, Gabra HOS, Bjornland K, Irtan S, Stenman J, Pio L, Cross KM, Avanzini S, Inserra A, Chacon JG, Dall'igna P, Von Schweinitz D, Holmes K, Fuchs J, Squire R, Valteau-Couanet D, Park JR, Eggert A, Losty PD, La Quaglia MP, Sarnacki S, Surgical and Medical Committees of SIOPEN*, COG** and GPOH***: A Novel Standard for Systematic Reporting of Neuroblastoma Surgery: The International Neuroblastoma Surgical Report Form (INSRF): A Joint Initiative by the Pediatric Oncological Cooperative Groups SIOPEN*, COG**, and GPOH**. Annals of surgery 2020 Jul 7; online ahaed of print [PMID: 32649454] MAT2020
  42. Koche RP, Rodriguez-Fos E, Helmsauer K, Burkert M, MacArthur IC, Maag J, Chamorro R, Munoz-Perez N, Puiggròs M, Dorado Garcia H, Bei Y, Röefzaad C, Bardinet V, Szymansky A, Winkler A, Thole T, Timme N, Kasack K, Fuchs S, Klironomos F, Thiessen N, Blanc E, Schmelz K, Künkele A, Hundsdörfer P, Rosswog C, Theissen J, Beule D, Deubzer H, Sauer S, Toedling J, Fischer M, Hertwig F, Schwarz RF, Eggert A, Torrents D, Schulte JH, Henssen AG: Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma. Nature genetics 2020, 52: 29 [PMID: 31844324] KOC2020
  43. Jazmati D, Butzer S, Hero B, Ahmad Khalil D, Merta J, Bäumer C, Plum G, Fuchs J, Koerber F, Steinmeier T, Peters S, Doyen J, Thole T, Schmidt M, Blase C, Tippelt S, Eggert A, Schwarz R, Simon T, Timmermann B: Proton Beam Therapy for Children With Neuroblastoma: Experiences From the Prospective KiProReg Registry. Frontiers in oncology 2020, 10: 617506 [PMID: 33552991] JAZ2020
  44. Berthold F, Faldum A, Ernst A, Boos J, Dilloo D, Eggert A, Fischer M, Frühwald M, Henze G, Klingebiel T, Kratz C, Kremens B, Krug B, Leuschner I, Schmidt M, Schmidt R, Schumacher-Kuckelkorn R, von Schweinitz D, Schilling FH, Theissen J, Volland R, Hero B, Simon T: Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. Annals of oncology : official journal of the European Society for Medical Oncology 2020, 31: 422 [PMID: 32067684] BER2020
  45. Matthyssens LE, Nuchtern JG, Van De Ven CP, Gabra HOS, Bjornland K, Irtan S, Stenman J, Pio L, Cross KM, Avanzini S, Inserra A, Chacon JG, Dall'igna P, Von Schweinitz D, Holmes K, Fuchs J, Squire R, Valteau-Couanet D, Park JR, Eggert A, Losty PD, La Quaglia MP, Sarnacki S, Surgical and Medical Committees of SIOPEN*, COG** and GPOH***: A Novel Standard for Systematic Reporting of Neuroblastoma Surgery: The International Neuroblastoma Surgical Report Form (INSRF): A Joint Initiative by the Pediatric Oncological Cooperative Groups SIOPEN*, COG**, and GPOH**. Annals of surgery 2020, [DOI: 10.1097/SLA.0000000000003947] MAT2020
  46. Moreno L, Barone G, DuBois SG, Molenaar J, Fischer M, Schulte J, Eggert A, Schleiermacher G, Speleman F, Chesler L, Geoerger B, Hogarty MD, Irwin MS, Bird N, Blanchard GB, Buckland S, Caron H, Davis S, De Wilde B, Deubzer HE, Dolman E, Eilers M, George RE, George S, Jaroslav Š, Maris JM, Marshall L, Merchant M, Mortimer P, Owens C, Philpott A, Poon E, Shay JW, Tonelli R, Valteau-Couanet D, Vassal G, Park JR, Pearson ADJ: Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. European journal of cancer (Oxford, England : 1990) 2020, 136: 52 [PMID: 32653773] MOR2020
  47. Berthold F: From a single meeting to a scientific community: Quantification of the . Pediatric blood & cancer 2019, 66:e27696 [PMID: 30848089] BER2019
  48. Thole TM, Toedling J, Sprüssel A, Pfeil S, Savelyeva L, Capper D, Messerschmidt C, Beule D, Groeneveld-Krentz S, Eckert C, Gambara G, Henssen AG, Finkler S, Schulte JH, Sieber A, Bluethgen N, Regenbrecht CRA, Kuenkele A, Lodrini M, Eggert A, Deubzer HE: Reflection of neuroblastoma intratumor heterogeneity in the new OHC-NB1 disease model. International journal of cancer 2019 Jul 15; [PMID: 31304977] THO2019
  49. Berthold F, Ernst A, Hero B, Klingebiel T, Kremens B, Schilling FH, Simon T: Correction: Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. British journal of cancer 2019 Sep 24; [PMID: 31551583] BER2019
  50. Kreitz K, Ernst A, Schmidt R, Simon T, Fischer M, Volland R, Hero B, Berthold F: A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis. Cancer medicine 2019 Oct 20; [PMID: 31631570] KRE2019
  51. Dübbers M, Simon T, Berthold F, Fischer J, Volland R, Hero B, Cernaianu G: Retrospective analysis of relapsed abdominal high-risk neuroblastoma. Journal of pediatric surgery 2018, 53: 558 [PMID: 29021103] DUE2018
  52. Berthold F, Ernst A, Hero B, Klingebiel T, Kremens B, Schilling FH, Simon T: Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. British journal of cancer 2018, 119: 282 [PMID: 29991700] BER2018
  53. Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, Bartenhagen C, Walter E, Gecht J, Kerschke L, Volland R, Menon R, Heuckmann JM, Gartlgruber M, Hartlieb S, Henrich KO, Okonechnikov K, Altmüller J, Nürnberg P, Lefever S, de Wilde B, Sand F, Ikram F, Rosswog C, Fischer J, Theissen J, Hertwig F, Singhi AD, Simon T, Vogel W, Perner S, Krug B, Schmidt M, Rahmann S, Achter V, Lang U, Vokuhl C, Ortmann M, Büttner R, Eggert A, Speleman F, O'Sullivan RJ, Thomas RK, Berthold F, Vandesompele J, Schramm A, Westermann F, Schulte JH, Peifer M, Fischer M: A mechanistic classification of clinical phenotypes in neuroblastoma. Science (New York, N.Y.) 2018 Dec 7; 362: 1165 [PMID: 30523111] ACK2018
  54. Berthold F, Spix C, Kaatsch P, Lampert F: Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015. Paediatric drugs 2017, 19: 577 [PMID: 28786082] BER2017a
  55. Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D, SIOP Europe Neuroblastoma Group (SIOPEN): Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. The Lancet. Oncology 2017, 18: 500 [PMID: 28259608] LAD2017
  56. Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD: Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert opinion on drug discovery 2017, 12: 801 [PMID: 28604107] MOR2017
  57. Fischer J, Pohl A, Volland R, Hero B, Dübbers M, Cernaianu G, Berthold F, von Schweinitz D, Simon T: Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months. BMC cancer 2017 Aug 4; 17: 520 [PMID: 28778185] FIS2017
  58. Peinemann F, van Dalen EC, Enk H, Berthold F: Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. The Cochrane database of systematic reviews 2017 Aug 25; 8:CD010685 [PMID: 28840597] PEI2017
  59. Hero B, Clement N, Oera I, Pierron G, Lapouble E, Theissen J, Pasqualini C, Valteau-Couanet D, Plantaz D, Michon J, Delattre O, Tardieu M, Schleiermacher G: Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome. Journal of pediatric hematology/oncology 2018, 40: 93 [PMID: 29135842] HER2017
  60. Berthold F, Hömberg M, Proleskovskaya I, Mazanek P, Belogurova M, Ernst A, Sterba J: Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. Pediatric hematology and oncology 2017, 34: 308 [PMID: 29148865] BER2017
  61. Simon T, Hero B, Schulte JH, Deubzer H, Hundsdoerfer P, von Schweinitz D, Fuchs J, Schmidt M, Prasad V, Krug B, Timmermann B, Leuschner I, Fischer M, Langer T, Astrahantseff K, Berthold F, Lode H, Eggert A: 2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. Klinische Padiatrie 2017, 229: 147 [PMID: 28561228] SIM2017
  62. Schmidt M, Hero B, Simon T: I-131-mIBG therapy in neuroblastoma: established role and prospective applications. Clinical and Translational Imaging 2016, Volume 4, Issue 2, 87 [DOI: 10.1007/s40336-016-0173-z] SCH2016e
  63. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS: Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. European journal of cancer (Oxford, England : 1990) 2016, 65: 1 [PMID: 27434878] MOR2016
  64. Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR: Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project. Pediatric blood & cancer 2014, [PMID: 25044743] MEA2014
  65. Simon T, Häberle B, Hero B, von Schweinitz D, Berthold F: Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013, 31: 752 [PMID: 23284039] SIM2013
  66. Simon T, Niemann CA, Hero B, Henze G, Suttorp M, Schilling FH, Berthold F: Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. Developmental medicine and child neurology 2012, 54: 347 [PMID: 22329756] SIM2012
  67. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, Berthold F: Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14. 18 or oral metronomic chemotherapy. BMC Cancer 2011, 18; 11: 21. [PMID: 21244693] SIM2011a
  68. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B: Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer 2011, 56: 578 [PMID: 21298742] SIM2011
  69. Sudbrock F, Schmidt M, Simon T, Eschner W, Berthold F, Schicha H: Dosimetry for (131)I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma. European journal of nuclear medicine and molecular imaging 2010, [PMID: 20179922] SUD2010
  70. Fischer M, Bauer T, Oberthür A, Hero B, Theissen J, Ehrich M, Spitz R, Eils R, Westermann F, Brors B, König R, Berthold F: Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene 2010, 29: 865 [PMID: 19901960] FIS2010
  71. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD, INRG Task Force: The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. Journal of clinical oncology 2009, 27: 298 [PMID: 19047290] MON2009
  72. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK, INRG Task Force: The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of clinical oncology 2009, 27: 289 [PMID: 19047291] COH2009
  73. Oberthuer A, Theissen J, Westermann F, Hero B, Fischer M: Molecular characterization and classification of neuroblastoma. Future oncology (London, England) 2009, 5: 625 [PMID: 19519203] OBE2009
  74. Hoene V, Fischer M, Ivanova A, Wallach T, Berthold F, Dame C: GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes. British journal of cancer 2009, 101: 1481 [PMID: 19707195] HOE2009
  75. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA: Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clinical chemistry 2009, 55: 1316 [PMID: 19460840] STU2009
  76. Benz-Bohm G, Hero B, Gossmann A, Simon T, Körber F, Berthold F: Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma How much diagnostic imaging is necessary? European journal of radiology 2009, [PMID: 19369017] BEN2009
  77. Voth H, Oberthuer A, Simon T, Kahlert Y, Berthold F, Fischer M: Co-regulated expression of HAND2 and DEIN by a bidirectional promoter with asymmetrical activity in neuroblastoma. BMC molecular biology 2009, 10: 28 [PMID: 19348682] VOT2009
  78. Theissen J, Boensch M, Spitz R, Betts D, Stegmaier S, Christiansen H, Niggli F, Schilling F, Schwab M, Simon T, Westermann F, Berthold F, Hero B: Heterogeneity of the MYCN oncogene in neuroblastoma. Clinical cancer research 2009, 15: 2085 [PMID: 19276282] THE2009
  79. Schmidt M, Simon T, Hero B, Schicha H, Berthold F: The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. European journal of cancer (Oxford, England : 1990) 2008, 44: 1552 [PMID: 18424129] SCH2008c
  80. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, Brors B, Beissbarth T, Vandesompele J, Pattyn F, Hero B, König R, Fischer M, Schwab M: Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome biology 2008, 9:R150 [PMID: 18851746] WES2008
  81. Bénard J, Raguénez G, Kauffmann A, Valent A, Ripoche H, Joulin V, Job B, Danglot G, Cantais S, Robert T, Terrier-Lacombe MJ, Chassevent A, Koscielny S, Fischer M, Berthold F, Lipinski M, Tursz T, Dessen P, Lazar V, Valteau-Couanet D: MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Molecular oncology 2008, 2: 261 [PMID: 19383347] BEN2008
  82. Oberthuer A, Kaderali L, Kahlert Y, Hero B, Westermann F, Berthold F, Brors B, Eils R, Fischer M: Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR. Clinical cancer research : an official journal of the American Association for Cancer Research 2008, 14: 6590 [PMID: 18927300] OBE2008
  83. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, van Noesel MM, Bierings M, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA: PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. Journal of clinical oncology 2008, 26: 5443 [PMID: 18838715] STU2008
  84. Fischer M, Spitz R, Oberthür A, Westermann F, Berthold F: Risk estimation of neuroblastoma patients using molecular markers. Klinische Padiatrie 2008, 220: 137 [PMID: 18478485] FIS2008
  85. Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, Schwabe D, Schilling FH, Benz-Bohm G, Berthold F: Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. Journal of clinical oncology 2008, 26: 1504 [PMID: 18349403] HER2008
  86. Voth H, Oberthuer A, Simon T, Kahlert Y, Berthold F, Fischer M: Identification of DEIN, a novel gene with high expression levels in stage IVS neuroblastoma. Molecular cancer research : MCR 2007, 5: 1276 [PMID: 18171985] VOT2007
  87. Simon T, Längler A, Berthold F, Klingebiel T, Hero B: Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 2007, 29: 101 [PMID: 17279006] SIM2007
  88. Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, Bongartz R, Berthold F, Schicha H: Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin. Nuclear medicine 2006, 45: 145-51; quiz N39 [PMID: 16964339] SCH2006b
  89. Oberthuer A, Warnat P, Kahlert Y, Westermann F, Spitz R, Brors B, Hero B, Eils R, Schwab M, Berthold F, Fischer M: Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. Cancer letters 2007, 250: 250 [PMID: 17126996] OBE2006a
  90. Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, Oestreich J, Fischer M, Simon T, Berthold F: Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes, chromosomes & cancer 2006, 45: 1130 [PMID: 16958102] SPI2006a
  91. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, König R, Haas S, Eils R, Schwab M, Brors B, Westermann F, Fischer M: Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006, 24: 5070 [PMID: 17075126] OBE2006
  92. Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H, Warnat P, Ernestus K, Hero B, Berthold F: Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clinical cancer research : an official journal of the American Association for Cancer Research 2006, 12: 5118 [PMID: 16951229] FIS2006
  93. Simon T, Hero B, Bongartz R, Schmidt M, Müller RP, Berthold F: Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease. Strahlentherapie und Onkologie 2006, 182: 389 [PMID: 16826357] SIM2006
  94. Spitz R, Hero B, Simon T, Berthold F: Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clinical cancer research 2006, 12(11 Pt 1): 3368 [PMID: 16740759] SPI2006
  95. Schumacher-Kuckelkorn R, Hero B, Ernestus K, Berthold F: Lacking immunocytological GD2 expression in neuroblastoma: report of 3 cases. Pediatric blood & cancer 2005, 45: 195 [PMID: 15800908] SCH2005a
  96. Hero B, Berthold F: Neuroblastoma. In: D. Reinhard (Hrsg.), Leitlinien Kinderheilkunde und Jugendmedizin Urban & Fischer, 2005, L5 1 [ISBN: 3-437-21867-0] HER2005
  97. Fischer M, Skowron M, Berthold F: Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. The Journal of molecular diagnostics 2005, 7: 89 [PMID: 15681479] FIS2005
  98. Wolfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, Ernestus K, Berthold F: Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer immunology, immunotherapy : CII 2005, 54: 400 [PMID: 15449039] WOE2005
  99. Eich HT, Muller RP, Micke O, Kocher M, Berthold F, Hero B: Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment? Strahlentherapie und Onkologie 2005, 181: 378 [PMID: 15925980] EIC2005
  100. Boensch M, Oberthuer A, Fischer M, Skowron M, Oestreich J, Berthold F, Spitz R: Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q. Diagnostic molecular pathology 2005, 14: 177 [PMID: 16106200] BOE2005
  101. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M, Simon T, Hero B: Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. The lancet oncology 2005, 6: 649 [PMID: 16129365] BER2005
  102. Simon A, Beutel K, Marklein G, Fleischhack G: Bacterial infections in pediatric cancer patients. Klin Pädiatr 2005, 217 Suppl 1:S17 [PMID: 16288351] SIM2005
  103. Claviez A, Lakomek M, Ritter J, Suttorp M, Kremens B, Dickerhoff R, Harms D, Berthold F, Hero B: Low occurrence of familial neuroblastomas and ganglioneuromas in five consecutive GPOH neuroblastoma treatment studies. European journal of cancer (Oxford, England : 1990) 2004, 40: 2760 [PMID: 15648116] CLA2004c
  104. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, Berthold F: Consolidation treatment with chimeric anti-GD2-antibody ch14. 18 in children older than 1 year with metastatic neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004, 22: 3549 [PMID: 15337804] SIM2004a
  105. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, Whiteford CC, Bilke S, Krasnoselsky AL, Cenacchi N, Catchpoole D, Berthold F, Schwab M, Khan J: Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer research 2004, 64: 6883 [PMID: 15466177] WEI2004a
  106. Jensen M, Tawadros S, Sedlacek HH, Schultze JL, Berthold F: NK cell depletion diminish tumour-specific B cell responses. Immunology letters 2004, 93(2-3): 205 [PMID: 15158618] JEN2004
  107. Spitz R, Hero B, Skowron M, Ernestus K, Berthold F: MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. European journal of cancer (Oxford, England : 1990) 2004, 40: 2753 [PMID: 15571958] SPI2004
  108. Schilling FH, Spix C, Berthold F, Erttmann R, Sander J, Treuner J, Michaelis J: Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany. Cancer letters 2003, 197(1-2): 19 [PMID: 12880955] SCH2003j
  109. Spitz R, Hero B, Ernestus K, Berthold F: Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2003, 9: 4835 [PMID: 14581355] SPI2003d
  110. Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling FH, Schrappe M, Simon T, Spix C: Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer letters 2003, 197(1-2): 11 [PMID: 12880954] BER2003a
  111. Simon T, Hero B, Hunneman DH, Berthold F: Tumour markers are poor predictors for relapse or progression in neuroblastoma. European journal of cancer (Oxford, England : 1990) 2003, 39: 1899 [PMID: 12932669] SIM2003a
  112. Krams M, Heidebrecht HJ, Hero B, Berthold F, Harms D, Parwaresch R, Rudolph P: Repp86 expression and outcome in patients with neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003, 21: 1810 [PMID: 12721258] KRA2003a
  113. Jensen M, Ernestus K, Kemshead J, Klehr M, Von Bergwelt-Baildon MS, Schinkothe T, Schultze JL, Berthold F: The bi-specific CD3 x NCAM antibody: a model to preactivate T cells prior to tumour cell lysis. Clinical and experimental immunology 2003, 134: 253 [PMID: 14616785] JEN2003